Observational studyWorld journal of urology2026
Predictors of surgical retreatment following Rezūm water vapor therapy: a multi-center real-world cohort study.
Observational study in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRezūm water vapor thermal therapy (WVTT) is an effective minimally invasive treatment for benign prostatic hyperplasia (BPH), offering durable symptom relief while preserving sexual function. However, real-world data on predictors of surgical retreatment remain limited. This study evaluates the incidence of surgical re-intervention following Rezūm therapy in a large multi-center cohort and identifies clinical and procedural factors associated with retreatment.
methodsA retrospective analysis was conducted using a prospectively maintained registry from two high-volume international centers in Canada and Italy. Men undergoing Rezūm therapy between April 2019 and August 2025 were included. Baseline demographics, comorbidities, functional outcomes, and intraoperative characteristics were compared between patients with and without surgical retreatment. Univariable and multivariable Cox proportional hazards models were used to evaluate predictors of time to re-intervention. Kaplan-Meier estimates were generated for cumulative incidence of retreatment.
resultsAmong 837 treated men, 43 (5.1%) underwent surgical retreatment over a median follow-up of three years. The cumulative probability of re-intervention was 2.3% at 1 year, 5.3% at 2 years, and 6.9% at 3 years. Most retreatment procedures consisted of GreenLight photovaporization (56%), TURP (20%), or repeat Rezūm (9%). Baseline demographic and clinical characteristics-including age, prostate volume, median lobe presence, medical therapy, and comorbidities-were not significantly associated with retreatment. The only baseline functional measure differing between groups was the BPH Impact Index (BPHII), which was higher among patients who required re-intervention (8.8 vs. 7.5, p = 0.010). In multivariable Cox analysis, BPHII remained independently predictive, with each one-point increase associated with an 18% higher hazard of retreatment (adjusted HR 1.18, p = 0.008).
conclusionIn this large, real-world multi-center cohort, Rezūm therapy demonstrated a low incidence of surgical retreatment for BPH.The BPHII emerged as the only independent predictor of retreatment, suggesting that patient-reported symptom impact may reflect disease severity or treatment resistance. These findings may support preoperative counseling and help guide patient selection for WVTT.
Indexed as
Identifiers
42371095What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.